Insider Trading Alert - TROX, CGIX And FLTX Traded By Insiders
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.
Yesterday, March 18, 2015, 90 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $500.00 to $102,376,000.00.
Highlighted Stocks Traded by Insiders:
Tronox (TROX) - FREE Research Report
Van Niekerk Willem Hendrik, who is Svp, Sp & Bd at Tronox, bought 1,000 shares at $20.10 on March 18, 2015. Following this transaction, the Svp, Sp & Bd owned 87,764 shares meaning that the stake was boosted by 1.15% with the 1,000-share transaction.
The shares most recently traded at $20.17, up $0.07, or 0.33% since the insider transaction. Historical insider transactions for Tronox go as follows:
- 4-Week # shares bought: 8,500
- 4-Week # shares sold: 19,000
- 12-Week # shares bought: 8,500
- 12-Week # shares sold: 19,000
- 24-Week # shares bought: 8,500
- 24-Week # shares sold: 19,000
The average volume for Tronox has been 638,900 shares per day over the past 30 days. Tronox has a market cap of $1.3 billion and is part of the basic materials sector and chemicals industry. Shares are down 14.78% year-to-date as of the close of trading on Wednesday.
Tronox Limited produces and markets titanium bearing mineral sands and titanium dioxide (TiO2) pigment in North America, Europe, South Africa, and the Asia-Pacific region. It primarily operates in two segments, Mineral Sands and Pigment. The stock currently has a dividend yield of 4.98%. Currently, there are 2 analysts who rate Tronox a buy, 1 analyst rates it a sell, and 1 rates it a hold.
Exclusive Offer: Get the latest Stock Analysis on TROX - FREE
rates Tronox as a
. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow, poor profit margins and generally high debt management risk. Get the full
from
now.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Cancer Genetics (CGIX) - FREE Research Report
Pappajohn John, who is Director at Cancer Genetics, bought 50,000 shares at $7.36 on March 18, 2015. Following this transaction, the Director owned 1.5 million shares meaning that the stake was boosted by 3.41% with the 50,000-share transaction.
Sitar Edward J, who is Chief Financial Officer at Cancer Genetics, bought 1,000 shares at $6.99 on March 18, 2015. Following this transaction, the Chief Financial Officer owned 12,500 shares meaning that the stake was boosted by 8.7% with the 1,000-share transaction.
The shares most recently traded at $8.11, up $1.12, or 13.79% since the insider transaction. Historical insider transactions for Cancer Genetics go as follows:
- 4-Week # shares bought: 5,589
- 12-Week # shares bought: 5,589
- 24-Week # shares bought: 82,269
The average volume for Cancer Genetics has been 65,500 shares per day over the past 30 days. Cancer Genetics has a market cap of $70.9 million and is part of the health care sector and health services industry. Shares are up 16.02% year-to-date as of the close of trading on Wednesday.
Cancer Genetics, Inc., an early-stage diagnostics company, focuses on developing and commercializing proprietary genomic tests and services to improve and personalize the diagnosis, prognosis, and response to treatment of cancer. Currently, there are 2 analysts who rate Cancer Genetics a buy, no analysts rate it a sell, and none rate it a hold.
Exclusive Offer: Get the latest Stock Analysis on CGIX - FREE
rates Cancer Genetics as a
. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, poor profit margins and generally disappointing historical performance in the stock itself. Get the full
Cancer Genetics Ratings Report
from
now.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
FleetMatics Group (FLTX) - FREE Research Report
Reynolds Andrew, who is Sr. VP, Global Bus. Developmen at FleetMatics Group, sold 4,375 shares at $43.69 on March 18, 2015. Following this transaction, the Sr. VP, Global Bus. Developmen owned 39,534 shares meaning that the stake was reduced by 9.96% with the 4,375-share transaction.
The shares most recently traded at $43.06, down $0.63, or 1.47% since the insider transaction.
The average volume for FleetMatics Group has been 404,400 shares per day over the past 30 days. FleetMatics Group has a market cap of $1.7 billion and is part of the technology sector and computer software & services industry. Shares are up 22.74% year-to-date as of the close of trading on Wednesday.
Fleetmatics Group PLC provides software-as-a-service fleet management solutions for small and medium-sized businesses (SMBs) worldwide. The company has a P/E ratio of 61.7. Currently, there are 4 analysts who rate FleetMatics Group a buy, no analysts rate it a sell, and 2 rate it a hold.
Exclusive Offer: Get the latest Stock Analysis on FLTX - FREE
rates FleetMatics Group as a
. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full
FleetMatics Group Ratings Report
from
now.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
null